文献速递放射性药物与辐射防护核素与放射性配体治疗肿瘤 PET/CT

FAP靶向放射偶联物的临床前特征:镥-177与铽-161的生物物理与药代动力学等效性评估

Preclinical characterization of FAP-targeting radioconjugates: assessing biophysical and pharmacokinetic equivalence of lutetium-177 and terbium-161.
PubMed 文献 · EJNMMI Res · 2026-07-29

该研究评估了177Lu标记的FAP抑制剂(FAPI-46、OncoFAP、FAP-2286、3BP-3940)及其161Tb标记类似物的生物物理特性和药代动力学。体外实验使用纤维肉瘤细胞,体内使用异种移植小鼠模型。结果显示161Tb标记偶联物在完整性、logD、细胞摄取、结合亲和力及体内分布方面与177Lu类似物相似,肿瘤摄取在注射后1小时达峰值后快速下降,提示可能需要重复给药以达到疗效。

要点

  • 161Tb标记的FAP靶向放射偶联物体外特性与177Lu类似物相似。
  • 小鼠体内分布显示两种放射性核素标记的偶联物分布轮廓一致。
  • 肿瘤摄取快速下降,3BP-3940在24小时仍保留6.4% IA/g。

核心结论

  • 161Tb标记的FAP靶向放射偶联物体外和体内特性与177Lu标记类似物相似。
  • 这些偶联物在小鼠HT1080-FAP肿瘤中积累较高,但活性随时间快速下降,可能需要重复给药以达到疗效。

研究设计与样本

  • 研究评估了177Lu标记的FAPI-46、OncoFAP、FAP-2286和3BP-3940及其161Tb标记类似物。
  • 体外使用纤维肉瘤肿瘤细胞,体内使用异种移植小鼠模型。

主要发现

  • 放射偶联物(500 MBq/mL)在盐水中24小时保持≥96%完整,与所用放射性核素无关。
  • 161Tb标记偶联物显示与177Lu类似物相似的logD值、HT1080-FAP细胞摄取和FAP结合亲和力(KD:0.48-1.8 nM)。
  • 体外结合小鼠和人血浆蛋白为中等程度,蛋白结合分数分别为39-56%和31-61%,与放射性核素无关。
  • 小鼠血浆中24小时孵育后完整分数≥87%,人血浆中≥91%,同一FAPI不同放射性核素标记间无差异。
  • HT1080-FAP/HT1080荷瘤小鼠中,161Tb基偶联物分布与177Lu类似物对应良好,注射后4小时双同位素SPECT/CT和定量生物分布数据证实。

关键数值与推荐

  • 放射偶联物在盐水中24小时完整性≥96%(500 MBq/mL)。
  • FAP结合亲和力KD范围为0.48-1.8 nM。
  • 小鼠血浆蛋白结合分数39-56%,人血浆蛋白结合分数31-61%。
  • 小鼠血浆24小时完整分数≥87%,人血浆≥91%。
  • 血液清除快速,给药后1小时滞留<1.5% IA/g;HT1080-FAP肿瘤摄取1小时达峰值8.8-20% IA/g,4小时降至7.4-11% IA/g,24小时降至<3% IA/g(3BP-3940例外,24小时为6.4±0.6% IA/g)。

临床怎么用

  • 161Tb标记的FAP靶向放射偶联物在临床前显示与177Lu类似物相似的生物分布,支持进一步开发。
  • 由于肿瘤活性快速清除,可能需要重复给药方案以达到治疗疗效。

局限性

  • 研究为临床前体外和小鼠模型,结果需临床验证。
  • 仅评估了四种FAP抑制剂,结论可能不适用于其他FAP靶向偶联物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radioconjugates targeting the fibroblast activation protein (FAP) have been successfully applied for nuclear imaging and are currently under investigation for radionuclide therapy. The aim of this study was to assess the biophysical properties of the 177Lu-labeled FAP inhibitors (FAPIs), FAPI-46, OncoFAP, FAP-2286 and 3BP-3940, and compare them with their 161Tb-labeled analogues. The respective 177Lu- and 161Tb-labeled FAPIs were evaluated using fibrosarcoma tumor cells in vitro and a xenograft mouse model to demonstrate pharmacokinetic equivalence. RESULTS: The radioconjugates (500 MBq/mL) remained ≥ 96% intact in saline over 24 h, irrespective of the employed radionuclide. The 161Tb-labeled conjugates showed similar logD values, uptake in HT1080-FAP cells and FAP-binding affinities (KD: 0.48-1.8 nM) as their 177Lu-based analogues. The in vitro binding to mouse and human blood plasma proteins was moderate with protein-bound fractions in the ranges of 39-56% and 31-61%, respectively, irrespective of the employed radionuclide. After 24 h incubation, the intact fraction of radioconjugates in mouse blood plasma was ≥ 87% while this was even ≥ 91% in human blood plasma without any differences among the same FAPIs labeled with either radionuclide. In HT1080-FAP/HT1080 tumor-bearing mice, the 161Tb-based FAP-targeting radioconjugates showed distribution profiles that corresponded well with their 177Lu-labeled analogues as demonstrated by dual-isotope SPECT/CT imaging and quantitative biodistribution data obtained at 4 h post-injection (p.i.). The radioconjugates were rapidly cleared from the blood, with < 1.5% IA/g retained at 1 h after administration. HT1080-FAP tumor accumulation reached its maximum with 8.8-20% IA/g at 1 h after injection of the radioconjugates, followed by gradual wash-out to 7.4-11% IA/g at 4 h p.i. and further to < 3% IA/g at 24 h p.i. An exception was the 3BP-3940 radioconjugate which still showed 6.4 ± 0.6% IA/g in the tumor xenograft at 24 h p.i.. CONCLUSION: The in vitro and in vivo properties of the 161Tb-labeled radioconjugates were similar to those of the 177Lu-labeled analogues. The accumulation of these FAP-targeting radioconjugates in HT1080-FAP tumors of mice was reasonably high, however, as the activity declined rapidly over time, repeated radioconjugate administration may be necessary to achieve therapeutic efficacy.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Mapanao AK, Adakli ES, Vaccarin C, et al. Preclinical characterization of FAP-targeting radioconjugates: assessing biophysical and pharmacokinetic equivalence of lutetium-177 and terbium-161. EJNMMI Res. 2026. PMID: 42931993. doi:10.1186/s13550-026-01488-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。